Vastarel MR 35 mg 30 tablets

Tradename:

Composition:

Each tablet contains:

Trimetazidine dihydrochloride 35.00 mg

Auxiliary components:

hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate.

Properties:

An agent that normalizes the energy metabolism of cells exposed to hypoxia or ischemia. Prevents a decrease in the intracellular content of ATP, ensures the normal functioning of membrane ion channels, transmembrane transport of potassium and sodium ions, and preservation of cellular homeostasis.

Trimetazidine slows down fatty acid oxidation by selectively inhibiting long-chain 3ketoacetyl-CoA thiolase, which leads to increased glucose oxidation and restoration of conjugation between glycolysis and oxidati decarboxylation, and has been shown to protect the myocardium from ischemia. Switching fatty acid oxidation to glucose

oxidation underlies the antianginal action of trimetazidine.

Indications:

Stable angina pectoris – as an adjunctive therapy in case of insufficient therapeutic effect or intolerance to first-line antianginal therapy.

Method of administration and dosage:

It is taken orally in a dose of 1 tablet 2 times / day with meals, morning and evening.

The duration of therapy is set individually, depending on the clinical situation.

Contraindications:

Pregnancy, lactation (breastfeeding), hypersensitivity to trimetazidine.

Precautions:

It is not intended for the relief of angina attacks and is not indicated for the initial course of therapy for unstable angina or myocardial infarction at the pre-hospital stage or in the first days of hospitalization.

Side effects:

Possibly: allergic reactions (including skin rash, itching), dizziness, headache.

Rarely: nausea, vomiting, gastralgia, tachycardia.

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box contains 3 blisters of 10 tablets, paper instructions.